Evidence map›Paper›PMID 37545626›Full record

ArticleOncology letters2023

Syndecan‑1 expression is an independent favourable prognostic marker in oesophageal adenocarcinoma and represents a potential therapeutic target.

Duygu Akca, Adrian Simon, Reinhard Buettner, Christiane Bruns, Wolfgang Schroeder, Thomas Zander, Florian Gebauer, Alexander Quaas

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Duygu AkcaDepartment of Pathology, Tekirdag Dr. Ismail Fehmi Cumalioglu City Hospital, 59030 Tekirdag, Turkey.
Adrian SimonInstitute of Pathology, University of Cologne, Faculty of Medicine and University Hospital Cologne, D-50937 Cologne, Germany.
Reinhard BuettnerInstitute of Pathology, University of Cologne, Faculty of Medicine and University Hospital Cologne, D-50937 Cologne, Germany.
Christiane BrunsDepartment of General, University of Cologne, Faculty of Medicine and University Hospital Cologne, D-50937 Cologne, Germany.
Wolfgang SchroederDepartment of General, University of Cologne, Faculty of Medicine and University Hospital Cologne, D-50937 Cologne, Germany.
Thomas ZanderDepartment I of Internal Medicine, Center for Integrated Oncology, University of Cologne, Faculty of Medicine and University Hospital Cologne, D-50937 Cologne, Germany.
Florian GebauerDepartment of General, University of Cologne, Faculty of Medicine and University Hospital Cologne, D-50937 Cologne, Germany.
Alexander QuaasInstitute of Pathology, University of Cologne, Faculty of Medicine and University Hospital Cologne, D-50937 Cologne, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Because of the poor prognosis of oesophageal adenocarcinoma (EAC), there is an urgent need for additional therapeutic approaches. Syndecan-1 (CD138) is a cell-surface heparan sulphate that is overexpressed in multiple myeloma cells and several carcinomas. Specific drugs targeting CD138 [e.g. antibody-linked drug conjugates (ADCs)] are currently being assessed; however, the significance and implication of CD138 expression in EAC is mostly unknown. In the present study, CD138 expression was assessed using immunohistochemistry, and its association with histopathological parameters and

Indexed as

antibody-linked drug conjugateBT062indatuximab ravtansineoesophageal cancerSDC1targeted therapies

Identifiers

PMID37545626
PMCPMC10398632

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.